𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunoaffinity measurement of recombinant granulocyte colony stimulating factor in patients with chemotherapy-induced neutropenia

✍ Scribed by Terry M. Phillips

Publisher
Elsevier Science
Year
1994
Weight
613 KB
Volume
662
Category
Article
ISSN
0378-4347

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant human granulocyte-macrophage
Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia
✍ Saarinen, Ulla M. ;Hovi, Liisa ;Riikonen, Pekka ;Pihkala, Jaana ;Juvonen, Eeva 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 721 KB

## Abstract Twenty children 1–17 (median, 5.5) years of age received GM‐CSF during chemotherapy‐induced neutropenia at the dose of 5 μg/kg/day, continued until the absolute neutrophil count (ANC) exceeded 500 × 10^6^/liter. Twelve children with solid tumors received GM‐CSF after courses of conventi

Granulocyte–colony-stimulating factor (f
Granulocyte–colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia
✍ Alfonso Quintas-Cardama; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Maner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract ## BACKGROUND Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous leukemia (CML). Although the safety profile of imatinib is favorable, Grade ≥ 3 neutropenia (according to the National Cancer Institute Common Toxicity Criteria) occurs in

Combination chemotherapy with granulocyt
Combination chemotherapy with granulocyte-macrophage–colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma
✍ Susan Partyka; Pamela Dumas; Jaffer Ajani 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

## BACKGROUND. A combination of etoposide, 5-fluorouracil, and folinic acid (ELF) remains popular for the treatment of patients with gastric carcinoma and has been reported to result in a response rate of up to 40% with good patient tolerance. The authors elected to add granulocyte-macrophage-colo